Stocks › BMRN
Biomarin Pharmaceutical Inc (BMRN) stock analysis
WEAK BUY 18% confidence · analysed Nov 3, 2026
On Nov 3, 2026, our model rated Biomarin Pharmaceutical Inc (BMRN) WEAK BUY with 18% confidence at a price of $55.66. That means the signals lean positive, but they are mixed, so conviction is low.
Technical picture
The 14-day RSI is 52, close to the neutral 50 line, so momentum is balanced.
MACD is above its signal line, a sign that short-term momentum is turning up.
The price is below both its 50-day and 200-day moving averages, the classic picture of a downtrend.
Volume is 1.8x its 20-day average, so the latest move has real participation behind it.
Trend structure and money flow
Market structure: ranging / no clear structure.
The most recent swing high is $70.98 and the swing low is $49.26; traders often treat these as resistance and support.
Price is sitting in a bullish order block, a zone where large buyers stepped in before.
Fundamentals
The PEG ratio is 0.34, which looks cheap relative to its expected growth.
The company reports a profit margin of 2.1% and revenue growth of +19.9%.
In its latest quarter it earned $0.23 per share, which beat the $-0.11 analysts expected, with revenue +19.9% year over year.
Wall Street's average rating is 1.7 on a 1 (strong buy) to 5 (sell) scale, roughly a "buy", with an average price target of $91.33.
The next earnings report is expected around Feb 22, 2027; prices often move sharply around earnings.
Trade plan from the model
The model's long / bullish plan uses an entry near $55.66, a target of $58.39 (+4.9%) and a stop-loss at $51.66 (-7.2%).
That is a reward-to-risk ratio of about 0.7 to 1: the potential loss is bigger than the gain, a weak setup.
The plan has a time limit: reassess by Nov 13, 2026 whatever the price does.
The model's one-paragraph read
Leans BUY — composite score +0.18 (WEAK BUY). Technicals: RSI 51.86, MACD bullish, price below SMA50. Fundamentals: PEG 0.34, margin 2.1%, revenue growth 19.9%. Financial results: YoY revenue +19.9%, last EPS surprise +309.1%, next earnings 2027-02-22. Smart Money Concepts: ranging / no clear structure, price retesting a bullish order block. FinGPT news read: positive. Suggested levels: entry $55.66, target $58.39, stop-loss $51.66, exit by 2026-11-13 (10-calendar-day max hold (time-stop; reassess by this date regardless of P&L)).
Past ratings for BMRN
| Date | Verdict | Confidence | Price | Move since | |
|---|---|---|---|---|---|
| Nov 3, 2026 | WEAK BUY | 18% | $55.66 | — |
"Move since" compares each call's price with the latest analysed price.
Recent news on BMRN
- Nov 3, 2026: BioMarin Beats Q3 Revenue Forecasts but Cuts 2026 Outlook on Voxzogo Timing and Deal Costs (InvestorsHub)
- Nov 2, 2026: BioMarin Tops Depressed EPS Bar And Crosses $1 Billion, But A Guidance Cut And Softer VOXZOGO Trends Complicate The Story (Earnings Whispers)
- Nov 2, 2026: BioMarin: Q3 Earnings Snapshot (Associated Press)
- Nov 2, 2026: BioMarin Reports Third Quarter 2026 Financial and Operating Results (PR Newswire)
Frequently asked questions
Is BMRN a buy right now?
As of Nov 3, 2026, our automated model rates Biomarin Pharmaceutical Inc (BMRN) WEAK BUY with 18% confidence: the signals lean positive, but they are mixed, so conviction is low. This is a model output for education, not personal investment advice.
What is the price target for BMRN?
The model's most recent plan targets $58.39 with a stop-loss at $51.66, from an entry near $55.66.
When does Biomarin Pharmaceutical Inc report earnings next?
The next earnings report is expected around Feb 22, 2027.
What does a WEAK BUY rating mean?
A WEAK BUY rating means the signals lean positive, but they are mixed, so conviction is low.
For information and education only. Not investment advice. Ratings are produced by an automated model, can be wrong, and may be out of date. Do your own research; you can lose money investing. The site's author may hold positions in stocks discussed here.